What is clinical indications and dosage and regimen for acamprosate?
Reading File
Finding Sources
Searching PubMed
acamprosate alcohol use disorder
Reading File
Reading File
Reading File
Reading File
Reading File
I now have thorough information from multiple authoritative textbooks. Here is a complete, well-organized answer:
Acamprosate - Clinical Indications, Dosage & Regimen
Clinical Indications
FDA-Approved Indication
Acamprosate is FDA-approved for the maintenance of abstinence from alcohol in patients with alcohol use disorder (AUD) who are already abstinent at the time treatment begins. Key caveats:
- It must be started only after the patient has been successfully detoxified from alcohol. It is not effective - and not indicated - in patients who have not undergone alcohol withdrawal before beginning treatment.
- It has not been demonstrated effective in patients with polysubstance abuse.
- Treatment must be part of a comprehensive management program that includes psychosocial support (counseling, support group attendance).
- Kaplan & Sadock's Synopsis of Psychiatry emphasizes: "It should only be started after the individual has been successfully weaned off alcohol."
Off-Label / Emerging Indications
- Fragile X syndrome (FXS) with co-occurring ASD: Preliminary and open-label trials show improvement in social-communicative behavior and inattention/hyperactivity. It is currently the preferred agent when FXS co-occurs with alcohol use disorder. (Mean dose used: ~1,221 mg/day)
- Sensorineural tinnitus: A double-blind, placebo-controlled crossover study (40 subjects, 45 days) showed significant reduction in tinnitus symptoms.
Mechanism of Action (Rationale for Use)
Acamprosate restores the neurochemical imbalance caused by chronic alcohol exposure:
- Chronic alcohol inhibits NMDA receptors, leading to upregulation of NMDA receptors and excess glutamate release. Abrupt cessation results in unopposed neuronal excitation - contributing to withdrawal syndrome and craving.
- Acamprosate acts as a weak NMDA receptor antagonist and a GABA-A/B receptor activator, dampening this excitatory excess.
- It also acts as an NMDA partial co-agonist - activating NMDA receptors at low activity states and inhibiting them at high activity, restoring equilibrium.
- It induces release of taurine (an inhibitory neuromodulator) and decreases dopamine hyperexcitability in the nucleus accumbens.
Dosage and Regimen
| Parameter | Details |
|---|---|
| Standard dose | 2 tablets (666 mg) three times daily |
| Tablet strength | Each tablet = 333 mg acamprosate calcium (equivalent to 300 mg acamprosate) |
| Daily total | 1,998 mg/day |
| Timing | Can be taken without regard to meals, but taking with meals is recommended to aid compliance in patients who eat 3 meals daily |
| Duration | Up to 1 year; treatment should continue even if relapse occurs |
Dose Adjustments
| Renal Function | Recommended Dose |
|---|---|
| Normal (CrCl > 50 mL/min) | 666 mg three times daily |
| Moderate impairment (CrCl 30-50 mL/min) | 333 mg (one tablet) three times daily |
| Severe impairment (CrCl < 30 mL/min) | Contraindicated - do not use |
- Hepatic impairment: No dose adjustment needed - acamprosate bypasses hepatic metabolism entirely and is excreted unchanged in urine and feces.
- Missed dose: Take as soon as remembered; skip if it is nearly time for the next dose. Do NOT double up.
Important Points
- Not for alcohol withdrawal: Acamprosate does not treat acute withdrawal symptoms (benzodiazepines are used for that).
- No abuse potential: There is no evidence of addiction or dependence with acamprosate.
- Discontinuation: No adverse effects occur with abrupt withdrawal, even after long-term use.
- Pregnancy: Teratogenicity has been demonstrated in animal studies (rat and rabbit fetuses). Not recommended; safety in humans is not established. Unknown if excreted in breast milk.
- Elderly: Evaluate renal function before initiating treatment, as renal clearance declines with age.
Adverse Effects
| System | Effects |
|---|---|
| GI (most common) | Diarrhea, nausea, vomiting, abdominal pain, flatulence |
| Neurological | Headache, paresthesias, somnolence, amnesia, tremor |
| Dermatological | Pruritus, rash, various skin reactions |
| Cardiovascular | Palpitations, syncope (rare) |
| Renal | Rare cases of acute renal failure reported (no causal link established) |
| Weight | Concomitant antidepressants increase risk of weight gain or loss |
Drug Interactions
- Alcohol, disulfiram, diazepam: Do not affect acamprosate's pharmacokinetics - no dose adjustments needed.
- Naltrexone: Co-administration increases acamprosate plasma concentrations; however, no dose adjustment is currently recommended. Naltrexone's own pharmacokinetics are unaffected.
- Minimal interactions overall: Because acamprosate undergoes no hepatic metabolism (no CYP450 involvement), it has very few clinically significant drug-drug interactions.
Clinical Efficacy Note
European trials consistently showed benefit (enhanced abstinence, reduced drinking days). However, the large U.S. COMBINE study found acamprosate did not show a statistically significant effect alone or in combination with naltrexone. The discrepancy is partly attributed to differences in study populations - European trials enrolled heavier drinkers with longer pre-treatment abstinence periods.
A 2023 JAMA systematic review and meta-analysis (PMID: 37934220) confirmed the evidence base for pharmacotherapy of AUD, with acamprosate remaining a recommended first-line option alongside naltrexone.
Sources:
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 11th ed.
- Kaplan & Sadock's Synopsis of Psychiatry
- Katzung's Basic and Clinical Pharmacology, 16th ed.
- Textbook of Family Medicine, 9th ed.
This is a shared conversation. Sign in to Orris to start your own chat.